Synthetic adjuvants:
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
New York u.a.
Wiley
1985
|
| Schriftenreihe: | Modern concepts in immunology
1 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XV, 239 S. |
| ISBN: | 0471864501 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV000468902 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t | ||
| 008 | 870612s1985 |||| 00||| eng d | ||
| 020 | |a 0471864501 |9 0-471-86450-1 | ||
| 035 | |a (OCoLC)11916002 | ||
| 035 | |a (DE-599)BVBBV000468902 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-12 | ||
| 050 | 0 | |a QR187.3 | |
| 050 | 0 | |a QW800 A193s 1985 | |
| 082 | 0 | |a 615/.19 |2 19 | |
| 082 | 0 | |a 616.07/9 |2 19 | |
| 100 | 1 | |a Adam, Arlette |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Synthetic adjuvants |
| 264 | 1 | |a New York u.a. |b Wiley |c 1985 | |
| 300 | |a XV, 239 S. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Modern concepts in immunology |v 1 | |
| 650 | 4 | |a Acetylmuramyl-Alanyl-Isoglutamine | |
| 650 | 4 | |a Adjuvants, Immunologic | |
| 650 | 4 | |a Adjuvants, Pharmaceutic | |
| 650 | 4 | |a Immunological adjuvants | |
| 650 | 0 | 7 | |a Adjuvans |0 (DE-588)4141430-5 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Adjuvans |0 (DE-588)4141430-5 |D s |
| 689 | 0 | |5 DE-604 | |
| 830 | 0 | |a Modern concepts in immunology |v 1 |w (DE-604)BV000019893 |9 1 | |
| 856 | 4 | 2 | |m GBV Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=000288985&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-000288985 | ||
Datensatz im Suchindex
| _version_ | 1804114921887105024 |
|---|---|
| adam_text | SYNTHETIC ADJUVANTS ARLETTE ADAM INSTITUTE OF BIOCHEMISTRY UNIVERSITY OF
PARIS-SUD ORSAY, FRANCE A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY &
SONS NEW YORK * CHICHESTER * BRISBANE * TORONTO * SINGAPORE CONTENTS 1.
MURAMYLPEPTIDES AND ANALOGUES 1 1.1. FROM FREUND S COMPLETE ADJUVANT TO
MURAMYLPEPTIDE 1 1.1.1. STRUCTURE OF PEPTIDOGLYCAN 2 1.1.2. ISOLATION OF
WATER-SOLUBLE ADJUVANTS 3 1.1.3. DEFINITION OF THE MINIMAL ADJUVANT
STRUCTURE 4 1.2. MURAMYLPEPTIDES AND DERIVATIVES 5 1.2.1. MODIFICATIONS
OF THE N-ACETYLMURAMYL GROUP 6 1.2.2. REPLACEMENT OF THE L-ALANYL
RESIDUE 7 1.2.3. SUBSTITUTION OF THE D-GLUTAMYL RESIDUE 8 1.2.4.
LIPOPHILIC DERIVATIVES 10 1.2.5. MDP CONJUGATES 13 1.2.6.
DESMURAMYLPEPTIDES AND PEPTIDOLIPIDS 14 1.3. ADJUVANT ACTIVITY 17 1.3.1.
QUALITATIVE CHANGES IN IMMUNOGLOBULIN PRODUCTION 18 1.3.2. CELL-MEDIATED
IMMUNITY 21 1.3.3. INDUCTION OF GRANULOMAS 22 IX 1.4. 1.5. 1.3.4. 1.3.5.
1.3.6. AUTOIMMUNE RESPONSES IMMUNOSUPPRESSION MECHANISM OF ACTION IN THE
STIMULATION IMMUNE RESPONSE NONSPECIFIC EFFECTS 1.4.1. 1.4.2. 1.4.3.
1.4.4. OTHER 1.5.1. 1.5.2. 1.5.3. 1.5.4. 1.5.5. 1.5.6. MITOGENIC
ACTIVITY POLYCLONAL ACTIVATION EFFECT ON NK CELL FUNCTIONS EFFECT ON
PHAGOCYTES BIOLOGIC ASPECTS IMMUNOGENICITY PYROGENICITY SOMNOGENIC
ACTIVITY MYELOPOIESIS AND OTHER EFFECTS METABOLIC FATE
TOXICOPHARMACOLOGICY SUMMARY CONTENTS 23 26 OF 31 35 35 36 37 37 47 47
48 50 52 54 55 56 1.6. 2. NUCLEIC ACID DERIVATIVES 59 2.1. 2.2. 2.3.
POLYRIBONUCLEOTIDES 2.1.1. ADJUVANT ACTIVITY 2.1.2. EFFECT ON
CELL-MEDIATED IMMUNITY 2.1.3. EFFECT ON MACROPHAGES 2.1.4. INDUCTION OF
INTERFERON 2.1.5. ACTION ON NK CELL ACTIVITY 2.1.6. TOXICOPHARMACOLOGY
INOSIPLEX 2.2.1. ADJUVANT ACTIVITY 2.2.2. NONSPECIFIC EFFECTS 2.2.3.
TOXICOPHARMACOLOGY HYPOXANTHINE DERIVATIVES 2.3.1. ADJUVANT ACTIVITY
2.3.2. NONSPECIFIC EFFECTS 2.3.3. TOXICOPHARMACOLOGY 59 60 61 63 64 66
68 68 69 70 73 74 75 77 78 CONTENTS XI 2.4. GUANOSINE DERIVATIVES 79
2.4.1. ADJUVANT ACTIVITY 79 2.4.2. MITOGENIC ACTIVITY 80 2.5. ADENINE
DERIVATIVES 81 2.6. PYRIMIDINONES 82 2.6.1. IMMUNOMODULATING PROPERTIES
83 2.6.2. INDUCTION OF INTERFERON 84 2.6.3. ACTION ON NK ACTIVITY 84
2.7. SUMMARY 85 3. SULFUR-CONTAINING COMPOUNDS 87 3.1. 3.2. 3.3. 3.4.
LEVAMISOLE 3.1.1. ADJUVANT ACTIVITY 3.1.2. EFFECTS OF LYMPHOCYTES 3.1.3.
PRODUCTION OF A THYMIC HORMONE- LIKE FACTOR 3.1.4. OTHER NONSPECIFIC
EFFECTS 3.1.5. MECHANISM OF ACTION 3.1.6. OTHER PHARMACOLOGIC ASPECTS
SODIUM DIETHYLDITHIOCARBAMATE 3.2.1. ADJUVANT ACTIVITY 3.2.2. PRODUCTION
OF A THYMIC HORMONE- LIKE FACTOR 3.2.3. EFFECT ON LYMPHOCYTES 3.2.4.
OTHER NONSPECIFIC EFFECTS 3.2.5. TOXICOPHARMACOLOGY CIMETIDINE 3.3.1.
ADJUVANT ACTIVITY 3.3.2. NONSPECIFIC EFFECTS 3.3.3. TOXICOPHARMACOLOGY
OTHER SULFUR-CONTAINING ADJUVANTS 3.4.1. THIABENDAZOLE 3.4.2.
DERIVATIVES OF IMIDAZOTHIAZOLE 3.4.3. 2-MERCAPTOETHANOL 3.4.4.
2-MERCAPTOPROPIONYLGLYCINE 87 88 89 90 91 92 93 94 94 95 96 97 98 98 99
100 101 101 101 103 104 105 XII CONTENTS 3.4.5.
N-(2-MERCAPTO-2-METHYLPROPANOYL) -L-CYSTEINE 105 3.4.6. D-PENICILLAMINE
105 3.5. SUMMARY 106 4. POLYMERS AND HETEROCYCLIC AND AROMATIC COMPOUNDS
109 4.1. PYRAN COPOLYMERS 109 4.1.1. ADJUVANT ACTIVITY 110 4.1.2. EFFECT
ON LYMPHOCYTES 111 4.1.3. EFFECT ON MACROPHAGES 112 4.1.4. EFFECT ON NK
CELL ACTIVITY 113 4.1.5. TOXICOPHARMACOLOGY 113 4.2. NED 137 114 4.3.
DEXTRAN SULFATE 115 4.3.1. ADJUVANT ACTIVITY 115 4.3.2. EFFECT ON
LYMPHOCYTES 115 4.4. PLURONIC POLYOLS 116 4.5. CYANAZIRIDINES 117 4.5.1.
IMMUNOMODULATING PROPERTIES 117 4.5.2. NONSPECIFIC EFFECTS 118 4.5.3.
EFFECT ON HEMOPOIESIS 119 4.5.4. TOXICOPHARMACOLOGY 119 4.6. TILORONE
120 4.6.1. IMMUNOMODULATING ACTIVITY 120 4.6.2. NONSPECIFIC EFFECTS 121
4.6.3. TOXICITY 121 4.7. SUMMARY 122 5. AMINE AND LIPID-CONTAINING
COMPOUNDS 123 5.1. DDA 123 5.1.1. ADJUVANT ACTIVITY 123 5.1.2.
NONSPECIFIC EFFECTS 125 5.2. CP-20,961 AND CP-46,665 126 5.2.1.
IMMUNOSTIMULATING PROPERTIES 126 CONTENTS X1U 5.2.2. EFFECT ON
AUTOIMMUNE DISEASES 127 5.2.3. EFFECT ON MACROPHAGES 128 5.3. CCA 128
5.4. ALKYLLYSOPHOSPHOLIPIDS 129 5.4.1. ADJUVANT ACTIVITY 130 5.4.2.
NONSPECIFIC EFFECTS 131 5.4.3. TOXICITY FOR TUMOR CELLS 131 5.4.4.
TOXICOPHARMACOLOGY 132 5.5. LIPID A ANALOGUES 133 5.5.1. ADJUVANT
ACTIVITY 133 5.5.2. NONSPECIFIC EFFECTS 134 5.5.3. ENDOTOXINLIKE
ACTIVITY 135 5.5.4. OTHER GLYCOLIPIDS 135 5.6. RETINOIDS 136 5.6.1.
ADJUVANT ACTIVITY 137 5.6.2. NONSPECIFIC EFFECTS 139 5.7. SUMMARY 139 6.
ADJUVANTS IN VACCINES 141 6.1. DEFINITION OF ANTIGENIC DETERMINANTS 142
6.2. MURAMYLPEPTIDES 144 6.2.1. CLASSICAL VACCINES 144 6.2.2. SYNTHETIC
VACCINES 147 6.3. POLYRIBONUCLEOTIDES * 149 6.4. LIPOIDAL AMINES 150
6.4.1. CP-20,961 150 6.4.2. DDA 151 6.5. SUMMARY 151 7. ADJUVANTS IN
NONSPECIFIC RESISTANCE TO INFECTIONS 153 7.1. MURAMYLPEPTIDES AND
DERIVATIVES 154 7.1.1. ACTIVITY IN NORMAL MICE 154 7.1.2. ACTIVITY IN
IMMUNOCOMPROMISED MICE 160 XIV CONTENTS 7.1.3. COMBINED THERAPIES 161
7.2. SULFUR-CONTAINING COMPOUNDS 163 7.2.1. LEVAMISOLE 163 7.2.2.
COMBINED THERAPIES 164 7.3. AZIMEXON 165 7.4. GLYCOLIPIDS 165 7.5.
ANTIVIRAL AGENTS 165 7.5.1. INOSIPLEX 165 7.5.2. PYRANS 167 7.5.3.
LIPOIDAL AMINES 167 7.6. INTERFERON INDUCERS 168 7.6.1. DOUBLE-STRANDED
RNA 168 7.6.2. PYRIMIDINONES 169 7.6.3. TILORONE 170 7.7. SUMMARY 171 8.
ADJUVANTS IN CANCER THERAPY 173 8.1. EVENTS AND TARGETS FOR THE ACTION
OF ADJUVANTS 173 8.1.1. SPECIFIC IMMUNITY 173 8.1.2. ACTIVATED
MACROPHAGES 175 8.1.3. NATURAL KILLER CELLS 177 8.2. ACTIVITY OF
MURAMYLPEPTIDES AND ANALOGUES 178 8.2.1. LIPOPHILIC DERIVATIVES 179
8.2.2. COMBINED THERAPY WITH MDP AND TDM * 181 8.2.3. COMBINED THERAPY
WITH LIPOSOME- ENCAPSULATED MDP AND SURGERY 182 8.3. ACTIVITY OF NUCLEIC
ACID DERIVATIVES 183 8.3.1. DOUBLE-STRANDED RIBONUCLEOTIDES 183 8.3.2.
PYRIMIDINONES 186 8.4. ACTIVITY OF SULFUR-CONTAINING ADJUVANTS 187
8.4.1. LEVAMISOLE 187 8.4.2. OTHER SULFUR-CONTAINING COMPOUNDS 190 8.5.
ACTIVITY OF POLYMERS AND HETEROCYCLIC AND AROMATIC ADJUVANTS 191
CONTENTS XV 8.5.1. PYRANS 191 8.5.2. NED 137 194 8.5.3. AZIMEXON 195
8.5.4. TILORONE 196 8.6. ACTIVITY OF LIPIDIC ADJUVANTS 197 8.6.1.
LIPOIDAL AMINES 197 8.6.2. ALKYLLYSOPHOSPHOLIPIDS 197 8.6.3. GLYCOLIPIDS
199 8.6.4. RETINOIDS 200 8.7. SUMMARY 201 CONCLUDING REMARKS 205
REFERENCES 209 INDEX 237
|
| any_adam_object | 1 |
| author | Adam, Arlette |
| author_facet | Adam, Arlette |
| author_role | aut |
| author_sort | Adam, Arlette |
| author_variant | a a aa |
| building | Verbundindex |
| bvnumber | BV000468902 |
| callnumber-first | Q - Science |
| callnumber-label | QR187 |
| callnumber-raw | QR187.3 QW800 A193s 1985 |
| callnumber-search | QR187.3 QW800 A193s 1985 |
| callnumber-sort | QR 3187.3 |
| callnumber-subject | QR - Microbiology |
| ctrlnum | (OCoLC)11916002 (DE-599)BVBBV000468902 |
| dewey-full | 615/.19 616.07/9 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics 616 - Diseases |
| dewey-raw | 615/.19 616.07/9 |
| dewey-search | 615/.19 616.07/9 |
| dewey-sort | 3615 219 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01431nam a2200421 cb4500</leader><controlfield tag="001">BV000468902</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">870612s1985 |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0471864501</subfield><subfield code="9">0-471-86450-1</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)11916002</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV000468902</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QR187.3</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QW800 A193s 1985</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615/.19</subfield><subfield code="2">19</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.07/9</subfield><subfield code="2">19</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Adam, Arlette</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Synthetic adjuvants</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York u.a.</subfield><subfield code="b">Wiley</subfield><subfield code="c">1985</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XV, 239 S.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Modern concepts in immunology</subfield><subfield code="v">1</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Acetylmuramyl-Alanyl-Isoglutamine</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Adjuvants, Immunologic</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Adjuvants, Pharmaceutic</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunological adjuvants</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Adjuvans</subfield><subfield code="0">(DE-588)4141430-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Adjuvans</subfield><subfield code="0">(DE-588)4141430-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Modern concepts in immunology</subfield><subfield code="v">1</subfield><subfield code="w">(DE-604)BV000019893</subfield><subfield code="9">1</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">GBV Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=000288985&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-000288985</subfield></datafield></record></collection> |
| id | DE-604.BV000468902 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-09T15:14:24Z |
| institution | BVB |
| isbn | 0471864501 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-000288985 |
| oclc_num | 11916002 |
| open_access_boolean | |
| owner | DE-12 |
| owner_facet | DE-12 |
| physical | XV, 239 S. |
| publishDate | 1985 |
| publishDateSearch | 1985 |
| publishDateSort | 1985 |
| publisher | Wiley |
| record_format | marc |
| series | Modern concepts in immunology |
| series2 | Modern concepts in immunology |
| spelling | Adam, Arlette Verfasser aut Synthetic adjuvants New York u.a. Wiley 1985 XV, 239 S. txt rdacontent n rdamedia nc rdacarrier Modern concepts in immunology 1 Acetylmuramyl-Alanyl-Isoglutamine Adjuvants, Immunologic Adjuvants, Pharmaceutic Immunological adjuvants Adjuvans (DE-588)4141430-5 gnd rswk-swf Adjuvans (DE-588)4141430-5 s DE-604 Modern concepts in immunology 1 (DE-604)BV000019893 1 GBV Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=000288985&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Adam, Arlette Synthetic adjuvants Modern concepts in immunology Acetylmuramyl-Alanyl-Isoglutamine Adjuvants, Immunologic Adjuvants, Pharmaceutic Immunological adjuvants Adjuvans (DE-588)4141430-5 gnd |
| subject_GND | (DE-588)4141430-5 |
| title | Synthetic adjuvants |
| title_auth | Synthetic adjuvants |
| title_exact_search | Synthetic adjuvants |
| title_full | Synthetic adjuvants |
| title_fullStr | Synthetic adjuvants |
| title_full_unstemmed | Synthetic adjuvants |
| title_short | Synthetic adjuvants |
| title_sort | synthetic adjuvants |
| topic | Acetylmuramyl-Alanyl-Isoglutamine Adjuvants, Immunologic Adjuvants, Pharmaceutic Immunological adjuvants Adjuvans (DE-588)4141430-5 gnd |
| topic_facet | Acetylmuramyl-Alanyl-Isoglutamine Adjuvants, Immunologic Adjuvants, Pharmaceutic Immunological adjuvants Adjuvans |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=000288985&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV000019893 |
| work_keys_str_mv | AT adamarlette syntheticadjuvants |